For GSK, declining costs boost margins as much as rising prices
Deregulated drug pricing is only part of the story for many pharmaceutical players, with a decline in global API prices boosting profits for some
Haleon investing heavily in Jamshoro factory expansion for exports
The Panadol manufacturer is betting big on its ability to tap into export markets for growth, starting with nutraceuticals
Amoxil recall hits GSK Pakistan revenue in otherwise strong year
Deregulated drug pricing allowed the company to improve gross margins, but the recall still caused revenue to decline
Liven Pharmaceuticals just made a rights issue. Will this prove to be the last throw of the dice?
The pharmaceutical company has had a torrid history. The new development could prove to be its redemption
At Searle, revenue growth is now about volumes, not just prices
The company has also managed to secure alternative input suppliers are disruption on trade with India
Descon Oxychem takes a hit as imports flood the market
Some exporting customers are allowed to purchase foreign competitors’ products, causing Descon to lose market share
As Panadol prices stabilise, Haleon’s revenue growth slows
The boost from deregulated drug prices is stalling, causing Haleon to look at new product launches in nutraceuticals and export markets for growth
Macter gaining market share, and diversifying into cosmetics
The biopharmaceutical manufacturer saw revenue growth faster than industry average, and also plans to launch a GLP 1 product
Afghan trade halt hits Pakistan’s $200 million pharma exports, medicine containers struck at Torkham, Chaman borders
PPMA warns over 50 pharma firms face losses as temperature-sensitive medicines risk expiry; industry urges govt to allow exports on humanitarian grounds
Senate panel alarmed as medicine prices jump 32% after price controls lifted
Health ministry reports some essential drugs have doubled in cost, prompting inquiry into deregulation impact; Pharmaceutical Manufacturers Association disputes the official figures
Govt backs PPMA’s expansion plans, discusses roadmap for $3 billion pharma export target by 2028
PharmEx Pakistan platform set to drive pharmaceutical exports to $3 billion in three years, and $10 billion over the next five years
Pakistan loses up to Rs50bn annually to unethical drug marketing, say DRAP officialsÂ
DRAP CEO says irrational drug use accounts for nearly a quarter of Pakistan’s total health budget and is accelerating antimicrobial resistanceÂ
DRAP’s survey on drug price hikes irks pharmaceutical manufacturers
Third-party survey initiated in response to public outcry over rising medicine prices after deregulation of non-essential drugs; PPMA voices concerns over lack of industry stakeholder involvement
Citi Pharma’s veterinary subsidiary begins operations, launching 32 products initially
Citi Veterinary Limited projects a turnover of Rs 1.5 billion for FY 2025-26, with plans to establish Pakistan's first dedicated veterinary Active Pharmaceutical Ingredient (API) plant
Searle secures DRAP’s approval for Denosumab biosimilar injections
Company prepares commercial rollout of 60mg and 120mg doses for osteoporosis and oncology care
